[Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].

Abstract

Tumor-induced osteomalacia (TIO) is a disease caused by fibroblast growth factor 23 (FGF23) secreted from the causative tumor. This disease is cured by complete surgical removal of the tumor. However, there are several difficult cases in which the responsible tumors cannot be found, are incompletely removed, or relapse after the surgery. Anti-FGF23 antibody is being studied as a novel therapy for FGF23-related hypophosphatemic diseases. The efficacy of anti-FGF23 antibodies were confirmed using a murine model of X-linked hypophosphatemic rickets (XLHR) , which is the most common heritable form of FGF23-related hypophosphatemic disease. In addition, results of phase I study of single injection of humanized anti-FGF23 antibody for adult patients with XLHR were recently published and the safety and effectiveness of this antibody was shown. This antibody therapy may be useful for patients with TIO with similar pathogenesis to that of XLHR.

• Authors: Yuka Kinoshita, Seiji Fukumoto
• Journal: Clinical calcium (Clin Calcium) Vol. 24 Issue 8 Pg. 1217-22 (Aug 2014) ISSN: 0917-5857 [Print] Japan
• PMID: 25065874 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies
• FGF23 protein, human
• Fibroblast Growth Factors
• Fibroblast Growth Factor-23

Topics

• Animals
• Antibodies (therapeutic use)
• Familial Hypophosphatemic Rickets (immunology, metabolism)
• Fibroblast Growth Factor-23
• Fibroblast Growth Factors (immunology)
• Humans
• Hypophosphatemia (etiology)
• Neoplasms, Connective Tissue (immunology, therapy)
• Osteomalacia (drug therapy, etiology, immunology)
• Paraneoplastic Syndromes